Header Logo

Connection

Oliver Brooks to Advisory Committees

This is a "connection" page, showing publications Oliver Brooks has written about Advisory Committees.
Connection Strength

1.222
  1. Use of COVID-19 Vaccines for Persons Aged =6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025. MMWR Morb Mortal Wkly Rep. 2024 Sep 19; 73(37):819-824.
    View in: PubMed
    Score: 0.229
  2. Use of an Additional Updated 2023-2024 COVID-19 Vaccine Dose for Adults Aged =65 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. MMWR Morb Mortal Wkly Rep. 2024 Apr 25; 73(16):377-381.
    View in: PubMed
    Score: 0.222
  3. Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine: Updated Interim Recommendations from the Advisory Committee on Immunization Practices - United States, December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 21; 71(3):90-95.
    View in: PubMed
    Score: 0.190
  4. The Advisory Committee on Immunization Practices' Interim Recommendations for Additional Primary and Booster Doses of COVID-19 Vaccines - United States, 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1545-1552.
    View in: PubMed
    Score: 0.187
  5. Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged =6 Months: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 20; 72(42):1140-1146.
    View in: PubMed
    Score: 0.054
  6. Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Aug 25; 72(34):920-925.
    View in: PubMed
    Score: 0.053
  7. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines - United States, October 2022. MMWR Morb Mortal Wkly Rep. 2022 Nov 11; 71(45):1436-1441.
    View in: PubMed
    Score: 0.050
  8. Interim Recommendation of the Advisory Committee on Immunization Practices for Use of the Novavax COVID-19 Vaccine in Persons Aged =18 years - United States, July 2022. MMWR Morb Mortal Wkly Rep. 2022 Aug 05; 71(31):988-992.
    View in: PubMed
    Score: 0.049
  9. Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022. MMWR Morb Mortal Wkly Rep. 2022 Jul 01; 71(26):859-868.
    View in: PubMed
    Score: 0.049
  10. The Advisory Committee on Immunization Practices' Interim Recommendation for Use of Pfizer-BioNTech COVID-19 Vaccine in Children Aged 5-11 Years - United States, November 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 12; 70(45):1579-1583.
    View in: PubMed
    Score: 0.047
  11. Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged =16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1344-1348.
    View in: PubMed
    Score: 0.046
  12. Serving as Trusted Messengers about COVID-19 Vaccines and Therapeutics. J Natl Med Assoc. 2021 Feb; 113(1):6-7.
    View in: PubMed
    Score: 0.044
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.